Waterman Capital, a private equity firm, completed the acquisition of Auckland Clinical Studies, a clinical research and pharmaceutical product development company, and Christchurch Clinical Studies Trust, a medical research company. Financial terms were not disclosed. The key attractions for Waterman included ACS’s and CCST’s outstanding global reputation, and the potential to further develop the New Zealand clinical research infrastructure with the promise of attracting more overseas Pharma and Biotech companies to this part of the world. This will result in better treatment options for patients in New Zealand.